Table 2.

Parameters of mineral metabolism and outcome variables at baseline and final follow-up at study end (12 weeks) in study participants with available values at both study visits.

	Baseline Visit		Study End		Treatment Effect
	Median	IQR	Median	IQR	Between Group Differences with 95% CI		p-Value
Mineral metabolism
25-hydroxyvitamin D (nmol/L)
Vitamin D (n = 96)	53	43–68	98	85–116	37.4	31.3 to 43.6	<0.001
Placebo (n = 96)	52	42–64	65	51–77
PTH (pg/mL)
Vitamin D (n = 94)	46.6	36.2–57.0	46.4	35.0–59.2	−4.8	−8.9 to −0.8	0.021
Placebo (n = 95)	43.4	35.8–54.3	49.3	38.7–61.6
Bone turnover markers
CTX (nmol/L)
Vitamin D (n = 94)	0.40	0.27–0.50	0.36	0.23–0.48	−0.01	−0.04 to 0.03	0.792
Placebo (n = 96)	0.35	0.27–0.50	0.36	0.27–0.45
Osteocalcin (ng/mL)
Vitamin D (n = 94)	20.9	16.7–25.5	21.5	17.6–27.8	0.84	−0.76 to 2.44	0.300
Placebo (n = 96)	21.2	16.8–24.3	20.3	17.7–23.9
BMD
Total body BMD (g/cm2)
Vitamin D (n = 94)	1.294	1.221–1.369	1.300	1.239–1.366	0.006	−0.006 to 0.020	0.293
Placebo (n = 92)	1.299	1.234–1.360	1.295	1.225–1.368
Lumbar spine BMD (g/cm2)
Vitamin D (n = 94)	1.233	1.106–1.334	1.227	1.100–1.345	0.002	−0.009 to 0.012	0.760
Placebo (n = 92)	1.213	1.110–1.315	1.219	1.099–1.326
Femoral neck BMD (g/cm2)
Vitamin D (n = 94)	1.027	0.932–1.143	1.037	0.928–1.141	0.002	−0.006 to 0.011	0.637
Placebo (n = 92)	1.022	0.956–1.120	1.012	0.943–1.113
Total hip BMD (g/cm2)
Vitamin D (n = 94)	1.073	0.993–1.184	1.075	0.984–1.177	−0.002	−0.009 to 0.006	0.662
Placebo (n = 92)	1.076	1.002–1.156	1.067	1.002–1.165
TBS
Vitamin D (n = 53)	1.357	1.313–1.521	1.375	1.273–1.484	0.037	−0.102 to 0.176	0.596
Placebo (n = 55)	1.382	1.351–1.445	1.378	1.319–1.418

IQR = interquartile range, PTH = parathyroid hormone, CTX = beta-crosslaps, BMD = bone mineral density, TBS = trabecular bone score. Data are shown as medians and interquartile range. Treatment effects with 95% confidence interval and p-values were calculated by ANCOVA for group differences at follow-up with adjustment for baseline values.